rucaparib
clovis
['gyn', 'ariel4', 'rucaparib', 'ovarian', 'brca', 'clovis']
updated results from the ariel4 trial, presented at #esmo22, prompted clovis oncology to withdraw the approval for rucaparib to treat brca-mutated ovarian cancer after 2 or more lines of chemotherapy. #gyncsm #gynonc 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.